The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Subscribe To Our Newsletter & Stay Updated
